HINGHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Harel Gadot, Chief Executive Officer, President, and Chairman, is scheduled to present at the Ladenburg Thalmann Healthcare Conference […]
Other News
ProtoKinetix Begins Cardiovascular Research
MARIETTA, Ohio–(BUSINESS WIRE)–ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences. Dr. Thomas Pulinilkunnil, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University is the principal investigator on this project. Pulinilkunnil laboratory […]
Amarin to Present at the Cantor Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 27, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present a general company update […]
Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in New York City
IRVINE, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, today announced that it will present and meet with potential investors at The MicroCap Conference on October 1 and 2 at The Essex […]
BIOSENSE WEBSTER ANNOUNCES FIRST PATIENTS ENROLLED IN POST-MARKET APPROVAL STUDY FOR ITS NOVEL TAG-INDEX GUIDED SOFTWARE
IRVINE, Calif., SEPTEMBER 26 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has received approval from the U.S. Food and Drug Administration (FDA) for its VISITAG SURPOINT External Processing Unit and enrollment has begun […]
Caladrius Biosciences to Participate in Upcoming October Conferences
BASKING RIDGE, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announced today that management will participate at the following conferences in October: 2018 Cell & Gene Meeting on […]
Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
CALGARY, Alberta, Sept. 27, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that at the Annual and Special Meeting of Shareholders (the “Meeting”) held on September 26, 2018, shareholders overwhelmingly approved all the resolutions placed before the Meeting and as outlined […]
LeMaitre Vascular Acquires Clot Management Business from Applied Medical
BURLINGTON, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it has acquired the vascular clot management business of Applied Medical Resources Corporation for $14.2 million, of which $11.0 million was paid at closing and $3.2 million will be paid in two post-closing installments. As […]
InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference
TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that preliminary cumulative three-year follow-up safety, efficacy and stroke prevention durability data from […]
TARA Biosystems Announces Launch of Cardiotype.Fo, Best-in-Class In Vitro Assay for Assessment of Cardiac Contractility
NEW YORK, Sept. 27, 2018 /PRNewswire/ — TARA Biosystems Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and development applications, announced today the launch of Cardiotype.Fo, the best-in-class in vitrosystem for assessment of cardiac contractility. Contractility of heart muscle tissue is a critically important measure of cardiac function and is used routinely […]
Recent
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
First Peer-Reviewed Study to Evaluate AI-Generated Impressions Demonstrates Radiologist Preference for Domain-Specific Versus General Models
Popular
- No commented posts yet